GlaxoSmithKline India in deal with Japanese Daiichi
New Delhi, May 14 (UNI) Pharma giant GlaxoSmithKline Pharmaceuticals Ltd today said it has signed a co-production agreement with Japanese drugmaker Daiichi Sankyo.
The company has signed a co-production agreement with Japanese drug maker Daiichi Sankyo for anti-hypertensive drug Olmesartan Medoxomil and its combination products, the company said in a statement.
However, the company refused to disclose any financial details.
UNI AK PDT DS1235
More From
-
Iran Rejects Trump’s Ceasefire Claim: Tehran Denies Talks, Calls It ‘US Retreat’ -
Tamil Nadu Opinion Poll: ANS Projects DMK Winning In 180 Seats In 234-Member Assembly -
Chennai Gold Silver Rate Today, 23 March 2026: Gold Price Hits 4-Month Low, Silver Slumps Amid Market Volatily -
Gold Silver Rate Today, 23 March 2026: City-Wise Prices, MCX Gold And Silver Extend March Weakness -
Passengers Evacuated After Air Canada Plane Reportedly Hits Fire Truck At LaGuardia -
Trump Announces 5-Day Strike Pause With Iran Amid Escalating West Asia War -
Oil Prices Slide, Stocks Recover Soon After Trump’s 'Ceasefire' Announcement -
Iran vs US-Israel War Halted? Breakthrough or Breather Before a Bigger Conflict -
Hyderabad Gold Silver Rate Today, 23 March 2026: Check Latest Gold And Silver Prices In The City -
Why Share Market Crashing Today: ₹13 Lakh Crore Wiped Out in Just 1 Hour, What Triggered Panic? -
“Thank You, India”: Iran Thanks Kashmir For Donations Of Gold, Cash And Livestock -
Why Indian Stock Market Is Down Today? Top Factors Behind ₹10 Lakh Crore Wealth Erosion
Click it and Unblock the Notifications
Sign in with Google